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1. Main Messages
•	 The	current	cervical	cancer	screening	program	would	become	more	efficient	if	the	starting	age	is	raised	to	25;	or	
the	screening	interval	is	extended	to	three	years;	or	a	more	accurate	screening	test	is	used.
•	 HPV	vaccination	of	12-year	old	girls	in	Australia	is	cost-effective	if	accompanied	by	a	screening	program	with	a	
starting	age	of	25	and/or	a	three-year,	instead	of	two-year	interval.
•	 HPV	DNA	testing	is	a	cost-effective	replacement	for	Pap	smear	screening.
•	 Primary	prevention	for	skin	cancer	by	SunSmart	is	cost-effective.
•	 Prostate	cancer	screening	using	the	PSA	test	decreases	health	at	a	cost,	and	should	be	avoided.
•	 The	one-year	course	of	Trastuzumab	for	early	breast	cancer	treatment	is	cost-ineffective.
2. Background
Cancer	is	one	of	the	National	Health	Priority	Area	and	currently	accounts	for	31%	of	male	deaths	and	26%	of	female	
deaths.	Cancer	contributed	19%	of	total	disability	adjusted	life	years	(DALYs),	representing	32.2%	of	years	of	life	
lost	(YLL)	and	6.5%	of	years	of	life	with	disability	(YLD),	as	the	greatest	cause	of	burden	in	Australia	in	2003.	The	
burden	from	cancer	is	significant	mainly	due	to	premature	death.	Some	cancers	have	modifiable	risk	factors;	others	
require	early	detection	to	reduce	the	mortality	and	morbidity.	The	primary	aim	of	this	paper	is	to	examine	the	cost-
effectiveness	of	primary	prevention	(vaccination	to	prevent	risk	factor	exposures)	for	cervical	cancer	and	secondary	
prevention	(early	detection	through	mass	screening)	for	cervical	and	prostate	cancer.	Another	primary	prevention	
intervention	for	skin	cancer	and	one	treatment	intervention	for	breast	cancer	as	a	benchmark	are	also	presented.
3. interventions
We	reviewed	current	policies	in	line	with	cancer	control	and	literature	to	identify	a	range	of	interventions	to	be	
evaluated.	While	some	interventions	are	currently	in	practice,	the	interventions	we	assessed	are	potential	options	for	
change	of	current	policy	based	on	existing	evidence	of	program	effectiveness	(SunSmart),	efficacy	of	vaccination,	
and	effectiveness	of	screening	tests.	Some	variations	in	screening	frequency	and	target	population	for	screening	
interventions	are	also	assessed.
nHMrc grant no. 351558
project leaders
prof tHeo vos (uQ)
prof roB carter (deakin)
paMpHlet autHor 
sopHY sHiH
for furtHer inforMation  
www.spH.uQ.edu.au/Bodce- 
ace-prevention
1. Pap test screening:	Routine	screening	by	conventional	Pap	test	in	women	who	have	ever	been	sexually	active	and	have	no	symptoms	or	
history	suggestive	of	cervical	pathology.
2. hPv dnA test screening:	Routine	screening	by	HPV	DNA	test	(Hybrid	Capture	II)	in	women	who	have	ever	been	sexually	active	and	have	
no	symptoms	or	history	suggestive	of	cervical	pathology.
3. Combined Pap test and hPv dnA test screening: Routine	screening	by	a	combination	of	conventional	Pap	test	and	HPV	DNA	test	
(positive	on	either	test	will	be	referred	for	further	investigation)	in	women	who	have	ever	been	sexually	active	and	have	no	symptoms	or	
history	suggestive	of	cervical	pathology.
4. hPv vaccination and Pap test screening:	Vaccinate	girls	at	age	12	in	2003	with	HPV1	vaccine	and	continue	screening	with	Pap	test.
5. hPv vaccination and hPv dnA test screening:	Vaccinate	girls	at	age	12	in	2003	with	HPV	vaccine	and	continue	screening	with	HPV	DNA	
test.
6. hPv vaccination and combined Pap and hPv dnA test screening:	Vaccinate	girls	at	age	12	in	2003	with	HPV	vaccine	and	continue	
screening	with	combined	Pap	and	HPV	DNA	test.
7. sunsmart program2  for skin cancer prevention:	An	on-going	national	SunSmart	program	with	increased	investment	at	$0.28	per	capita	
for	the	next	20	years.	
8. screening for prostate cancer:	a	one-off	screening	test	for	prostate	specific	antigen	(PSA)	in	the	male	population	aged	55-70	in	2003.	
Comparator	is	no	screening.
9. trastuzumab (herceptintm) treatment for breast cancer:	adjuvant	trastuzumab	and	chemotherapy	(ATC)	for	all	newly	diagnosed	breast	
cancer	aged	30-100	with	positive	human	epidermal	growth	factor	receptor	2	(HER2)	in	2003.	Comparator	is	no	trastuzumab.
4. cHoice of coMparator
Unless	stated	otherwise,	the	comparator	to	the	interventions	is	current	practice.	Current	practice	for	cervical	cancer	screening	is	a	2-yearly	
screening	in	women	aged	18	to	69	by	conventional	Pap	test	delivered	through	the	National	Cervical	Screening	Program.	
5. intervention cost-effectiveness
Prior	to	introduction	of	HPV	vaccination	program,	changing	current	cervical	screening	to	a	less	resource-intensive	scenario	will	save	money	but	
with	a	considerable	health	loss	(Intervention	A	&	B	in	Table	1).	Though,	cervical	screening	could	be	improved	by	adding	HPV	DNA	testing	to	Pap	
screen	with	extended	screening	frequency	or	delaying	age	at	commencing	screening,	without	health	loss	(Intervention	E	and	F	in	Table	1).	
After	introduction	of	HPV	vaccination	program,	current	cervical	screening	can	be	changed	to	a	more	relaxed	program	because	of	enormous	
health	gain	provided	by	HPV	vaccination.	With	HPV	vaccination	program	in	place,	the	current	screening	program	should	extend	screening	
frequency	to	3	years	and/or	increase	the	screening	starting	age	to	25,	which	would	save	large	amount	of	costs	in	screening	and	management/
treatment	for	an	abnormal	Pap	test	(to	offset	the	vaccination	program	cost).		
(Intervention	H	and	I	in	Table	1).
The	SunSmart	program	also	demonstrates	health	gain	and	net	cost	saving,	when	compared	to	current	practice,	from	Australian	Government	
perspective	as	a	third-party	funder.	From	a	broader	health	sector	perspective	to	include	individual	costs,	it	still	achieves	a	good	cost-effectiveness	
result	(Intervention	N	in	Table	1).	
Prostate	cancer	screening	does	decrease	prostate	cancer	mortality,	but	at	the	cost	of	a	large	increase	in	diagnosed	and	treated	cases	
(overtreatment).	Because	of	the	severe	side-effects	of	treatment,	the	increase	in	morbidity	outweighs	the	mortality	benefit,	and	on	balance	there	
is	health	loss	with	an	increase	in	costs	(dominated).	
The	one-year	course	of	trastuzumab	for	early	breast	cancer	is	cost-ineffective,	mainly	because	of	the	very	high	costs		
(Intervention	P	in	Table	1).
1	 Quadrivalent	human	papillomavirus	(HPV)	types	6/11/16/18	L1	virus-like	particle	(VLP)	vaccine.
2	 SunSmart	program	is	a	skin	cancer	prevention	program	which	incorporates	mass	media	work,	resource	development	and		
dissemination,	professional	education,	advocacy	of	policy	development	and	a	strong	research	and	evaluation	component.
Table	1:	Incremental	cost-effectiveness	ratios	(ICER)	for	all	interventions,	when	compared	to	current	practice
*	 	Dominant	means	health	gain	with	cost	saving.
#		 Modelled	population	varies	by	intervention;	therefore	the	health	gain	for	these	2	interventions	is	not	comparable	to	that	of	other	interventions.
^		 Interventions	with	health	loss	and	less	cost	fall	in	quadrant	3:	there	is	some	health	loss	but	with	cost	saving;	a	greater	ICER	is	more	favourable	and	values	greater	than	
$50,000	per	DALY	would	indicate	that	this	intervention	is	more	efficient	and	desirable.
		3	 The	base	case	of	HPV	vaccination	intervention	is	based	on	assumption	of	full	vaccination	protection	for	5	years	and	then	declining	at	rates	determined	by	loss	of	detectable	serum		
HPV	antibody.
Intervention DALY averted Incremental  
net cost ($m)
ICER $/DALY
base case3  (ranges)
Pap test screening
A. Pap screen every 2 year from age 25 -100 -15.1 health loss with less cost
152,000^
B. Pap screen every 3 year from age 18 -393 -29.2 health loss with less cost
74,000^
HPV DNA test screening
C. HPV DNA test screen every 3 year from age 18 59 0.6 11,000
Combined Pap and HPV DNA test screening
D. Combined Pap screen and HPV DNA test screen 
every 3 year from age 18
190 16.0 84,000
E. Pap screen for age 18-29 and combined screen 
from age 30 every 3 year
84 -1.4 Dominant*
F. Combined screen every 3 year from age 25 156 -1.9 Dominant*
HPV vaccination and Pap test  screening
G. HPV vaccination at age 12 and Pap screen every 
2 year from age 18
786 35.9 46,000   
(40,000 - 55,000)
H. HPV vaccination at age 12 and Pap  screen every 
2 year from age 25
765 20.8 27,000   
(23,000 – 34,000)
I. HPV vaccination at age 12 and Pap screen every 
3 year from age 18
679 8.5 12,000   
(10,000 – 18,000)
HPV vaccination and HPV DNA test screening
J. HPV vaccination at age 12 and HPV DNA test 
screen every 3 year from age 18
828 33.9 41,000   
(36,000 - 49,000)
HPV vaccination and combined Pap &  
HPV DNA test screening
K. HPV vaccination at age 12 and combined Pap & 
HPV DNA test screen every 3 year from age 18
878 49.3 56,000   
(51,000 – 65,000)
L. HPV vaccination at age 12 and Pap screen for 
age 18-29 and combined screen from age 30 
every 3 year
857 33.7 39,000   
(35,000 – 46,000)
M. HPV vaccination at age 12 and combined Pap & 
HPV DNA test screen every 3 year from age 25
873 32.9 38,000   
(34,000 – 44,000)
SunSmart program for skin cancer prevention #
N. SunSmart program for 20 years 120,000 2,000 16,000  
(12,000 – 22,000)
Screening for prostate cancer
O. One-off screening for males 55-70 in 2003 -3,400 Not calculated Health loss with  
higher costs
Trastuzumab treatment for breast cancer #
P. Adding trastuzumab (HerceptinTM) to standard 
chemotherapy for all newly diagnosed breast 
cancer with positive human epidermal growth 
factor receptor 2
1366 131.8 96,000  
(73,000 - 139,000)
ACE–PrEvEntion PAmPhlEts
6. conclusions
Current	practice	already	prevents	between	half	and	two	thirds	of	cervical	cancer.	The	proposed	screening	strategies	make	small	
adjustments	to	existing	gains	from	current	practice.	The	efficiency	of	the	current	screening	program	could	be	improved	by	more	
accurate	screening	tests	(HPV	DNA	testing	instead	of	Pap	smears);	with	a	later	starting	age	(25	instead	of	18);	and	with	a	longer	
screening	interval	(3	instead	of	2	years).	The	newly	introduced	HPV	vaccination	of	12	year	old	girls	is	cost-effective	if	combined	
with	the	above	recommended	changes	to	the	screening	program.	
Strength	of	evidence	is	the	most	important	of	the	second-stage	filter	criteria	in	evaluating	cervical	cancer	prevention	
interventions.	These	results	are	sensitive	to	screening	test	accuracy	(sensitivity	and	specificity)	and	the	assumptions	about	the	
largely	unobserved	natural	history	of	early	lesions	and	cancer.	Duration	of	vaccine	immunity	is	another	key	element	in	the	
determination	of	cost-effectiveness.	Clinical	trials	have	demonstrated	immunity	for	at	least	5	years.	Long	term	efficacy	of	the	
vaccine	is	critical	in	estimation	of	health	outcomes	but	is	yet	to	be	determined	by	future	clinical	studies.	Substitution	by	other	
malignant	HPV	strains	and	cross-protection	of	vaccine	on	infection	by	other	HPV	strains	are	uncertain	and	to	be	determined	by	
future	studies	too.		
Primary	prevention	for	skin	cancer	by	SunSmart	is	cost-effective,	achieving	health	gain	and	net	cost	saving,	from	Australian	
Government	perspective.	From	a	broader	health	sector	perspective,	it	is	still	cost-effective.	
Prostate	cancer	screening	with	PSA	should	be	avoided,	because	it	adds	to	costs	at	a	loss	of	health.	Treatment	for	early	breast	
cancer	with	Trastuzumab	is	cost-ineffective.
For	more	information	on	this	topic	area,	please	visit	website		www.sph.uq.edu.au/bodce-ace-prevention
 7. aBout ace-prevention
To	aid	priority	setting	in	prevention,	the	Assessing	Cost-Effectiveness	in	Prevention	Project	(ACE-Prevention)	applies	
standardised	evaluation	methods	to	assess	the	cost-effectiveness	of	100	to	150	preventive	interventions,	taking	a	health	sector	
perspective.	This	information	is	intended	to	help	decision-makers	move	resources	from	less	efficient	current	practices	to	more	
efficient	preventive	action	resulting	in	greater	health	gain	for	the	same	outlay.
indigenous population results 
1.			Cardiovascular	disease	prevention	
2.			Diabetes	prevention	
3.			Screening	and	early	treatment	of	chronic	kidney	disease
overall results 
1.			League	table	
2.			Combined	effects	
General population results
1.		 Adult	depression
2.		 Alcohol
3.		 Blood	pressure	and	cholesterol	lowering
4.		 Cannabis
5.		 Cervical	cancer	screening,	Sunsmart	and	PSA	screening
6.		 Childhood	mental	disorders
7.		 Fruit	and	vegetables
8.	 HIV
9.	 Obesity
10.	 Osteoporosis
11.	 Physical	activity
12.	 Pre	diabetes	screening
13.	 Psychosis
14. Renal replacement therapy, screening and early  
treatment of chronic kidney disease
15. Salt
16. Suicide prevention
17. Tobacco 
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methods: 
A.			The	ACE-Prevention	project	
B.			ACE	approach	to	priority	setting	
C.			Key	assumptions	underlying	the	economic	analysis	
D.			Interpretation	of	ACE-Prevention	cost-effectiveness	results	
E.			Indigenous	Health	Service	Delivery	
